Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel pandemic virus. Mounting evidence supports the possibility of vertical transmission, which at the present time appears to be rare. We report a newborn with vertically acquired SARS-CoV-2 who developed acute respiratory failure and received remdesivir and coronavirus disease 2019 convalescent plasma.

In this clinician-therapeutic drug monitoring (TDM) consultant interaction, the authors describe the use of TDM in an 11year-old female patient with cystic fibrosis receiving ceftazidime/ avibactam and aztreonam for the treatment of persistent pulmonary exacerbations caused by Stenotrophomonas pneumonia. Serum drug concentrations at a steady state confirmed inadequate antimicrobial exposure, and continuous infusions of both ceftazidime/avibactam and aztreonam were required to optimize the percentage of time when free drug remained above the minimum inhibitory concentration (MIC), known as fT . MIC. After dose adjustment, this continuous infusion strategy resulted in 100% target attainment for fT . MIC. This case illustrates the importance of TDM, and the logistical issues encountered with the use of alternative dosing strategies in pediatric patients with CF.

What is known an objective Our objective is to report a paediatric case of high‐level ceftaroline resistance without previous ceftaroline exposure. Case description A 20‐month‐old, 12 kg, female with invasive MRSA infection presented with high‐level ceftaroline resistance with no previous ceftaroline exposure. What is new and Conclusion To our knowledge, our case is the first report of high‐level ceftaroline resistance evident in a paediatric patient with invasive infection due to MRSA, without history of prior ceftaroline exposure. This case illustrates the importance of weighing the risk of resistance with the benefits of use when starting therapy empirically prior to susceptibility results, even in patients without previous drug exposure.